1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference20 articles.
1. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group;Cairncross;J Clin Oncol,1994
2. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumours: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971;van den Bent;J Clin Oncol,2003
3. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas;Brada;Ann Oncol,2003
4. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy;Chinot;J Clin Oncol,2001
5. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas;Cairncross;J Natl Cancer Inst,1998
Cited by 104 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evaluation of the effectiveness of multicomponent treatment in the progression of primary low-grade brain gliomas. Own experience;Russian Journal of Oncology;2023-12-27
2. A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas;Cancers;2023-06-06
3. Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone for Resected Oligodendroglioma: A Surveillance, Epidemiology and End Results (SEER) Analysis;World Neurosurgery;2023-02
4. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH;The Journal of Molecular Diagnostics;2021-09
5. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series;Clinical Neurology and Neurosurgery;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3